Standard Biotools Inc (LAB) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Standard Biotools Inc   (NASDAQ: LAB)


Standard Biotools Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Standard Biotools Inc's ROI in the second quarter of 2026?
Standard Biotools Inc achieved a return on average invested assets (ROI) of 16.5 % in its second quarter of 2026, this is above LAB's average return on investment of -22.67%.
Standard Biotools Inc invested over the 12 months ending in its second quarter of 2026 $515 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 29 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 454, from total ROI ranking in the first quarter of 2026 at 459.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -1.49 % -12.13 % -20.23 % -2.74 % 19.94 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 570 597 459 432 459
Return On Investment (TTM) 16.5 % 16.07 % -15.99 % -26.17 % -23.07 %
LAB's Overall Ranking # 454 # 459 # 2691 # 2309 # 2709
Seq. Investment Change TTM 5.73 % 3.93 % -4.44 % -6.19 % -5.69 %
Seq. Net Income Change TTM 8.57 % - - - -
Net Income (TTM) in Millions 85 78 -75 -128 -121

LAB Company Profile >> Back to LAB Roi Comparisons >> See Annual LAB Return On Investment



Return On Investment LAB's Ranking
Within: No.
Industry # 2
Sector # 30
Overall # 454

Return On Investment Statistics
High Average Low
16.38 %
-22.67 %
-58.08 %
(Jun 30 2026)   (Jun 30 2022)







Financial Statements
Standard Biotools Inc's II. Quarter Investments $ 570 Millions LAB's Balance sheet
Standard Biotools Inc's II. Quarter Income $ -27 Millions Quarterly LAB's Income Statement
LAB's Income by Division See LAB's Income by Division


LAB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 459 546 214 347 226
Y / Y Investment Growth -15.92 % 155.66 % -38.38 % 53.72 % -16.58 %
Net Income in Millions -75 -139 -75 -190 -59
Y / Y Net Income Growth - - - - -
Annual Return On Investment -16.3 % -25.42 % -34.93 % -54.8 % -26.25 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Laboratory Analytical Instruments Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LAB's Roi Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LAB's Competitors
Subscribers only: Roi for Standard Biotools Inc's Suppliers
Subscribers only: Return On Investment for LAB's Customers

Other Ratios
LAB's Roa LAB's Inventory Turnover Ratio LAB's Growth Rates LAB's Dividend Statistics
LAB's Profitability Ratios LAB's Asset Turnover Ratio LAB's Dividend Growth
LAB's Roe LAB's Valuation Ratios LAB's Financial Strength Ratios LAB's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %

Date modified: 2026-09-01T20:00:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.